[Skip to the guide](#guide) [NextGen](/) [Compare](/compare/) [Questions](/faq/) [About](/about/) [Guide](/) Semaglutide / GENERATION 01 / ONE TARGET # Compounded semaglutide, clearly explained. This page explains semaglutide and compounding: making a medicine to order. Products approved by the U.S. Food and Drug Administration (FDA) exist. Compounded semaglutide is not FDA-approved. The ingredient name alone does not describe a product’s approval or its suitability for a person. TODAY / U.S. ONLY [Start a Promise Peptides visit for semaglutide](https://mypromise.com/products/semaglutide?utm_source=nextgen&utm_medium=affiliate&utm_campaign=compound&utm_content=hero) Promise Peptides prescribes now. A licensed provider reviews each request and decides whether to prescribe. Not everyone qualifies. Compounded medicines are made to order, not FDA-approved. NextGen may earn money when readers become Promise patients. TARGET STUDY / 01 GLP-1 GLP-1 is a hormone signal. A receptor is a cell’s signal receiver. Semaglutide acts on one receptor type. 01 ## The first step on the target ladder. Semaglutide is a peptide, a short chain of protein building blocks. It acts on the GLP-1 receptor. A receptor is a part of a cell that receives a signal. GLP-1 is the name of a natural hormone signal in the body. Semaglutide is a man-made, altered copy of that hormone. The technical term is receptor agonist: a compound that activates a receptor. In this guide, that makes it our one-target generation. Tirzepatide acts on two receptor types. Retatrutide, still investigational, acts on three. Those counts help explain the designs. A higher count does not decide which medicine, if any, is appropriate for someone. [Follow the generation ladder](/compare/) 02 ## Approval belongs to a specific medicine. FDA is short for the U.S. Food and Drug Administration. Its approval concerns a finished medicine. The existence of an approved semaglutide product does not give approval to every product called semaglutide. Compounding means making a medicine to order. Compounded semaglutide is not FDA-approved. The FDA does not check the safety, quality or effectiveness of a compounded medicine before it is sold. A pharmacy licence is also different from product approval. Compounded medicines are not FDA-approved. A pharmacy licence does not change that status. 03 ## Compounding has limits. Compounding can address a patient's medical need that an approved product cannot meet. The law limits routine copies of medicines already available. A licensed provider must consider the individual need and the rules that apply. A useful question is: What exact product is being considered, and why? Other questions include which pharmacy would be involved and what follow-up the provider would arrange. This page cannot answer those questions for an individual. 04 ## A label cannot review your health. A research-only sale may carry the words “not for human use.” That order does not include a provider assessing your health. The FDA has warned about unapproved semaglutide sold with research labels and about products of unknown quality. A clinical review concerns a person as well as a product. Medical history, other medicines and pregnancy plans can be relevant. A provider decides whether care is appropriate; finding a familiar ingredient name online does not settle it. 05 ## The linked U.S. route starts with review. Promise prescribes semaglutide and tirzepatide now through licensed U.S. providers. A provider reviews every request and decides whether to prescribe. Not everyone qualifies. A licensed U.S. provider reviews each request and makes the prescription decision. A product choice does not guarantee a prescription. Medications are prepared by licensed U.S. compounding pharmacies. Compounded medications are not FDA-approved. Promise is for U.S. patients only. Availability varies by state and by treatment. Promise is LegitScript-certified. This is a private check of business standards, not FDA approval or a rating of medical care. 06 ## Reading behind this page. 01 / [Semaglutide: approved product information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) Records the GLP-1 target and the status of a specific approved semaglutide product. 02 / [FDA: risks of compounded medicines](https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs) Explains that compounded medicines do not receive FDA approval before they are sold. 03 / [FDA: what compounding means](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) Explains medicines made to order and how they differ from FDA-approved products. ## The next step is a question about care. Promise prescribes semaglutide and tirzepatide now through licensed U.S. providers. A provider reviews every request and decides whether to prescribe. Not everyone qualifies. TODAY / U.S. ONLY [Start a Promise Peptides visit for semaglutide](https://mypromise.com/products/semaglutide?utm_source=nextgen&utm_medium=affiliate&utm_campaign=compound&utm_content=closing) Promise Peptides prescribes now. A licensed provider reviews each request and decides whether to prescribe. Not everyone qualifies. Compounded medicines are made to order, not FDA-approved. NextGen may earn money when readers become Promise patients. [Retatrutide](/retatrutide/) [Tirzepatide](/tirzepatide/) [Semaglutide](/semaglutide/) [About](/about/) [References](/references/) [Contact](/contact/) [Promise Peptides: weight visit](https://mypromise.com/products?utm_source=nextgen&utm_medium=affiliate&utm_campaign=compound&utm_content=footer) NextGen may earn money when readers become Promise patients. NextGen is not affiliated with any company that has used the name NextGen Peptides or Next Gen Peptides. NextGen puts peptide questions into plain words; it is a guide, not a clinic, pharmacy or seller. Facts reviewed 8 October 2026 [Read as Markdown](/semaglutide/index.md)